Evidence map›Paper›PMID 41922680›Full record

ArticleScientific reports2026

Co-delivery of cisplatin and Bmi1 siRNA via nanocapsules overcomes chemoresistance in ovarian cancer.

Mengbin Liu, Xing Liu, Junru Heng, Changping Li, Yunlong Duan, Qi Fu, Jun Shen, Binbin Zhang, Shaohua Zhang, Yingying Xie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mengbin LiuThe Clinical Medical School, Qinghai University Affiliated Hospital, Qinghai University, 251 Ningda Road, Xining, 810000, Qinghai Province, China.
Xing LiuWuhan Pulmonary Hospital, Wuhan, 430030, China.
Junru HengThe Clinical Medical School, Qinghai University Affiliated Hospital, Qinghai University, 251 Ningda Road, Xining, 810000, Qinghai Province, China.
Changping LiThe Clinical Medical School, Qinghai University Affiliated Hospital, Qinghai University, 251 Ningda Road, Xining, 810000, Qinghai Province, China.
Yunlong DuanThe Clinical Medical School, Qinghai University Affiliated Hospital, Qinghai University, 251 Ningda Road, Xining, 810000, Qinghai Province, China.
Qi FuThe Clinical Medical School, Qinghai University Affiliated Hospital, Qinghai University, 251 Ningda Road, Xining, 810000, Qinghai Province, China.
Jun ShenThe Clinical Medical School, Qinghai University Affiliated Hospital, Qinghai University, 251 Ningda Road, Xining, 810000, Qinghai Province, China.
Binbin ZhangThe Clinical Medical School, Qinghai University Affiliated Hospital, Qinghai University, 251 Ningda Road, Xining, 810000, Qinghai Province, China.
Shaohua ZhangWuhan Asia Heart General Hospital, Wuhan, 430030, China.
Yingying XieThe Clinical Medical School, Qinghai University Affiliated Hospital, Qinghai University, 251 Ningda Road, Xining, 810000, Qinghai Province, China. xyy09001@126.com.

Funding

Innovation and Entrepreneurship Fund of Qinghai University CXCY202408Natural Science Foundation of China 81760276
6 · The paper itself

Abstract

Ovarian cancer (OC) is a leading cause of gynecological cancer mortality, primarily due to chemotherapy resistance and tumor recurrence. Cancer stem cells (CSCs), regulated by key factors like Bmi1, play a pivotal role in this resistance by maintaining CSC self-renewal and promoting tumor progression. However, effective treatments targeting these mechanisms remain limited. We engineered a lipid-coated calcium carbonate-based nanocapsule system (CCL) for co-delivery of cisplatin and Bmi1 siRNA (CCL@Bmi1 siRNA) to overcome cisplatin resistance in OC. Bioinformatics analysis revealed significant upregulation of Bmi1 in OC tissues, correlating with poor prognosis. In vitro, CCL@Bmi1 siRNA significantly enhanced cisplatin sensitivity in resistant SK-OV-3/DDP cells. In vivo studies using xenograft and primary ovarian cancer mouse models demonstrated marked tumor growth suppression following treatment with CCL@Bmi1 siRNA, without notable systemic toxicity. Immunohistochemical analyses showed reduced expression of CSC-associated and multidrug resistance markers in tumor tissues. These findings suggest that Bmi1-targeted co-delivery nanotherapeutics represent a promising strategy to counteract chemoresistance and improve therapeutic outcomes in OC.

Indexed as

Antineoplastic AgentsCisplatinDrug Resistance, NeoplasmNanocapsulesOvarian NeoplasmsPolycomb Repressive Complex 1RNA, Small InterferingAnimalsCell Line, TumorFemaleHumansMiceNeoplastic Stem CellsXenograft Model Antitumor AssaysAntineoplastic AgentsBMI1 protein, humanCisplatinNanocapsulesPolycomb Repressive Complex 1RNA, Small InterferingCancer stem cellsCisplatin resistantCo-delivery systemOvarian cancer

Identifiers

PMID41922680
PMCPMC13181104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.